At rennesens GmbH the enormous potential of biotechnology is used to achieve significant improvements in medical diagnostics.
In co-operation with other biotechnological companies in Germany rennesens GmbH develops new test methods, based on molecular and nanotechnological processes.
With CardioDetect™ rennesens GmbH offered worldwide the first rapid test card that detects the new cardiac marker
h-FABP, facilitating a much earlier diagnosis and appropriate treatments of patients with acute myocardial infarction. |
